Physician profile
Danny Wong
NPI 1306336755
$8,765.78
in general payments reported to CMS, 2019-2025
24 companies · $6,396 in 2025
The $6,396 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,370 · 2025: $6,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,755 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,755.30 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,288.42 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $2,014.81 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,281.42 | 2024-2025 | Entyvio |
| Qol Medical, LLC | $580.49 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $489.92 | 2024-2025 | Xifaxan |
| Pfizer INC. | $417.03 | 2024-2025 | |
| Lilly USA, LLC | $276.78 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $212.85 | 2024-2025 | Dupixent |
| Celgene Corporation | $157.45 | 2024 | Zeposia |
| Organon LLC | $155.46 | 2024-2025 | Hadlima |
| Janssen Scientific Affairs, LLC | $150.00 | 2025 | Tremfya |
| Merck Sharp & Dohme LLC | $148.84 | 2024 | Dificid |
| Exact Sciences Corporation | $111.71 | 2025 | Cologuard Collection Kit |
| Celltrion USA INC. | $108.44 | 2024-2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $95.04 | 2024-2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $77.00 | 2024-2025 | Hyrimoz |
| Ardelyx, INC. | $43.53 | 2024-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $40.79 | 2024-2025 | Vowst |
| Daiichi Sankyo INC. | $24.84 | 2024 | Injectafer |
| Braintree Laboratories, INC. | $23.77 | 2024 | Suflave, Sutab |
| Vibrant Gastro, INC. | $21.00 | 2025 | Vibrant Starter Kit |
| Amgen INC. | $18.34 | 2025 | Uplizna |
| Vivus LLC | $17.37 | 2024 | Qsymia |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.